A novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence-free survival in patients with prostate cancer.

ABSTRACT:

Objective

To identify molecular clusters and develop a novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence free survival (BCRFS) and tumor immune microenvironment of prostate cancer (PCa).

Materials and methods

We obtained the clinical and transcriptome data of PCa from TCGA and GEO database. Univariate and multivariate Cox regression analysis were used to establish a novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting BCRFS. To evaluate the validity of the risk score, both internal and external validations were carried out. Preliminary in-vivo and in-vitro experimental validations were performed to verify the biological functions of NOG in PCa docetaxel resistance.

SUBMITTER: Zhu D 

PROVIDER: S-EPMC12357823 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature